Table 2.

Concentrations of resveratrol and its major metabolites in normal tissue (proximal or distal to the tumor) and tumor tissue, obtained from the right (cecum, ascending colon, hepatic flexure) or left side (splenic flexure, descending colon, sigmoid colon, rectum) of the colorectum, in patients who received resveratrol daily for 8 days at 0.5g.

Species	Tissue Levels (nmol/g)*
	Proximal to Tumor		Tumor		Distal to Tumor
	Left	Right	Left	Right	Left	Right
Resveratrol	0.67±0.72 (0–3.0)	18.6±17.4 (0–45.9)	0.63±0.69 (0–1.80)	8.33±6.06 (3.1–15.0)	0.48±0.47 (0–1.04)	4.94±4.82 (1.95–13.5)
Resveratrol-3-O-glucuronide	loq**	86.0±125 (0–317)	lod	0.73±1.26 (0–2.18)	loq	0.64±0.46 (0–0.94)
Resveratrol-4′-O-glucuronide	0.17±0.34 (0–0.93)	7.91±11.2 (0–28.2)	loq	0.29±0.50 (0–0.87)	0.28±0.43 (0–0.99)	lod
Resveratrol sulfate glucuronide	17.1±20.8 (0–61.1)	44.5±47.9 (0–149)	12.8±15.9 (0–34.6)	5.09±7.86 (0–14.2)	20.0±39.7 (0–121)	lod
Resveratrol-3-O-sulfate	0.82±0.77 (0–2.84)	34.0±48.6 (0.67–128)	0.44± 0.70 (0–1.90)	3.09±2.13 (0.68–4.75)	0.94±1.17 (0–3.40)	2.37±0.43 (1.86–2.93)
Resveratrol-4′-O-sulfate	loq	1.21±1.78 (0–4.52)	0.25± 0.43 (0–1.02)	0.26±0.46 (0–0.79)	lod	0.17±0.38 (0–0.85)

^*Values are the mean±SD of 7 samples from tissues in the left side and 3 from the right side, with one tumor sample and between 1 and 3 normal tissue samples (proximal or distal to the tumor) per patient. Range in brackets.

^**loq=close to or below the limit of quantitation; lod=below the limit of detection.